1.This assay is designed for detecting MET gene amplification status, primarily in human non-small cell lung cancer, and can guide targeted therapy with crizotinib.
2.MET amplification occurs in various tumor types (including breast cancer, ovarian cancer, lung cancer, thyroid carcinoma, etc.), is associated with poor prognosis, and is closely linked to resistance to EGFR-TKIs.